Pain Management Rheumatoid Arthritis Data Focussed Commentary

To visit another floor: Press the lift button, use the HTML version, or go to the reception
.

Data focused Commentary

Knowledge Laboratory

- Case Studies

- Quizzes

Library

Patient Decision Aids

Workshops

- <60 minute eLearning event

- Key slides

Information Mastery 1 - Introduction
Information Mastery 2 - Skills
Musculoskeletal Pain
Pain overview
NPCi blog - Rheumatoid arthritis

SIGN Guidance - (Management of Early Rheumatoid Arthritis)
Clinical Knowledge Summary (PRODIGY) - rheumatoid arthritis
NICE Guidance on the coxibs - TA27
British Society for Rheumatology Guideline for the management of rheumatoid arthritis in first 2 years
NICE guidance on the management of rheumatoid arthritis in adults
NICE guidance on rituximab - TA126
NICE guidance on certolizumab pegol - TA186
NICE guidance on abatacept - TA141
NICE guidance on adalimumab, etanercept and infliximab - TA 130

Please help us to improve this site by filling in our feedback form

Pain Management

Rheumatoid Arthritis -

Data Focussed Commentary

Changes/additions to materials (reviewed 20/07/10):

NICE has published the final appraisal determination (FAD) regarding drugs for the treatment of rheumatoid arthritis after failure of a TNF inhibitor. A FAD is also available for tocilizumab for rheumatoid arthritis. Please note that these are not final guidance, which is expected to be published in August 2010.

NICE has published guidance (TA186) recommending certolizumab pegol▼ as an option for the treatment of adults with rheumatoid arthritis (RA) only if:

the drug is used in the same way as defined in the NICE TA130 for adalimumab▼, etanercept▼ and infliximab, and
the manufacturer provides the first 12 weeks of certolizumab pegol▼ free of charge to all patients starting treatment.

More information is contained in the NPCi blog.

We have produced data-focussed commentaries to highlight areas where there appear to be differences between the evidence-base, as described elsewhere on this floor, and current clinical practice. These resources can be read on the screen by clicking the 'flash' version, or by downloading and printing the 'PDF' version.

This commentary discusses English prescribing data relating to the use of DMARDs (disease modifying anti-rheumatic drugs), and highlights key points for prescribers and commissioners relating to other drugs used in RA. English prescribing data relating to NSAIDs (including coxibs) is discussed on the musculoskeletal pain floor of NPCi.

Date of last update: March 2010

Flash	Click here to view the Rheumatoid Arthritis Data Focussed Commentary online
PDF	Download a copy of the Rheumatoid Arthritis Data Focussed Commentary

Data focussed commentaries are written in the context of careful consideration of the available evidence. There are limits to the interpretation of data and assuming it is a true reflection of clinical practice. Nevertheless, we regard the issues represented within data focussed commentaries as being legitimate issues for debate.

Terms & Conditions